Mexico Periodontal Therapeutics Market Analysis

Mexico Periodontal Therapeutics Market Executive Summary

Mexico Periodontal Therapeutics Market is at around $13.1 Mn in 2023 and is projected to reach $21.6 Mn in 2030, exhibiting a CAGR of 7.45% during the forecast period.

Periodontal disease, often known as gum disease, is a dangerous dental ailment that is associated with gum inflammation and infection. Periodontitis is a common condition often caused by inadequate oral hygiene that can be largely avoided with the use of therapeutic, non-surgical, or surgical treatment approaches. Treating periodontitis with antibiotics alone is known as periodontal therapy, a relatively new yet successful treatment strategy that is becoming more and more popular among patients and dentists. Amoxicillin, doxycycline, and metronidazole are common antibiotics used in periodontal therapy. As adjuvant therapy, a variety of mouthwashes and rinses containing antimicrobial substances such as hydrogen peroxide, chlorhexidine, and essential oils can reduce gingival inflammation and plaque.

The prevalence of periodontal disease in Mexico is significant, with studies indicating that over 80% of the population experiences some form of periodontal issues. Demographic factors such as age, socioeconomic status, and urban versus rural residence play crucial roles; older adults and those with lower socioeconomic status are particularly at risk. Healthcare expenses for periodontal treatment are considerable, with rising costs attributed to the growing demand for dental services and advancements in treatment technologies. Therefore, the market is driven by significant factors like High Prevalence of periodontitis, Emphasis on Preventive Oral Care, and Shift Towards Minimally Invasive Treatments. However, Limited insurance coverage for periodontal treatments, Adverse Effects, and High Cost restrict the growth and potential of the market.

OraVu®, which is a dental technology company dealing in dental endoscopy solutions, launched a complete micro-endoscope system called DeVA-1® Dental Vision Assistant.

Market Dynamics

Market Growth Drivers

High Prevalence of Periodontitis: The widespread prevalence of periodontal disease, impacting almost 80% of the population, has driven up the demand for both non-surgical and surgical periodontal treatments. This increasing burden, notably among aging individuals and those with diabetes, underscores the need for advanced diagnostic tools, preventive strategies, and innovative treatment options. Enhanced awareness and the improvement of healthcare infrastructure further stimulate market growth, making the high prevalence of periodontal disease a vital driver for market expansion and investment.

Emphasis on Preventive Oral Care:  Nutritional counselling, stress management, and smoking cessation are incorporated into comprehensive care plans. For instance, studies indicate that integrating these strategies can reduce the incidence of periodontal disease by up to 40%. Regular dental visits serve as opportunities for systemic health screenings, further enhancing patient care. Patient education extends to the oral-systemic health connection, emphasizing the profound impact of periodontal health on overall health.

Shift Towards Minimally Invasive Treatments: The trend towards minimally invasive dentistry and conservative periodontal treatments promotes the adoption of non-surgical periodontal therapies, such as scaling and root planning (SRP), local antimicrobial agents, and adjunctive periodontal medications, as first-line interventions for managing periodontal diseases. Minimally invasive approaches preserve periodontal tissues, minimize patient discomfort, and promote faster healing, supporting patient acceptance, treatment compliance, and long-term periodontal health outcomes.

Market Restraints

Limited insurance coverage for periodontal treatments: Many insurance plans offer 25% coverage for periodontal treatments, leaving a substantial portion of the population unable to afford advanced procedures like gum surgeries and periodontal therapy. This lack of coverage particularly affects lower-income groups and those without private insurance, leading to delayed treatment and exacerbation of oral health issues.

Adverse Effects: Mexico faces restraints due to the perceived risks of anaesthesia-related side effects during periodontal surgeries, which may include nausea, dizziness, or allergic reactions. These concerns can influence patient decision-making regarding undergoing complex periodontal procedures. Moreover, negative experiences or outcomes from treatment can lead to reduced trust and reluctance to pursue further periodontal care, impacting the overall market demand.

High cost: The public healthcare system provides limited coverage for advanced dental procedures, pushing many patients to seek expensive private care. The disparity in economic conditions means that specialized treatments like implants and bone grafting are out of reach for a significant portion of the population. In Mexico, this affects approximately 30% of individuals who cannot afford these treatments due to financial constraints.

Regulatory Landscape and Reimbursement scenario

The regulatory landscape for the periodontics market in Mexico is governed by the Federal Commission for Protection Against Sanitary Risks (COFEPRIS), which oversees medical and dental practices. Compliance with the Official Mexican Standards (NOMs), such as NOM-013-SSA2-2015, which sets guidelines for the prevention and control of oral diseases, is mandatory. Additionally, dental professionals must be licensed and adhere to continuing education requirements. The market is influenced by evolving healthcare policies, increasing emphasis on quality standards, and the integration of advanced technologies, aimed at enhancing patient care and ensuring safety.

Public insurance programs, like Seguro Popular, cover basic dental treatments but often exclude specialized periodontal procedures. Private health insurance plans offer more comprehensive coverage, including advanced periodontal treatments, yet these plans are accessible primarily to higher-income individuals. Out-of-pocket payments remain common, particularly for costly procedures such as dental implants and grafts. To address affordability issues, some clinics offer financing options. Overall, while access to basic periodontal care is relatively widespread, financial barriers persist for advanced treatments, underscoring a need for broader insurance coverage and affordability initiatives.

Competitive Landscape

Key Players

Here are some of the major key players in Mexico Periodontal Therapeutics Market:

• Pfizer Inc.
• Lupin Ltd
• Teva Pharmaceuticals USA, Inc.
• Sun Pharmaceutical Industries Ltd.
• Tokyo Chemical Industry Co., Ltd.
• Bausch Health Companies Inc.
• Melinta Therapeutics LLC
• Cipla, Inc.
• Chartwell Pharmaceuticals LLC.
• ASA Dental S.p.A.
• Steris-Hu-Friedy
• Carl Martin GmBH